Beaumont Financial Partners Has Decreased Abbott Laboratories (ABT) Stake; 1 Bullish Analysts Covering Nuveen Build America Bond Opportunity Fund (NBD)

February 19, 2018 - By Elijah Rosenthal

Among 2 analysts covering Norbord (NYSE:NBD), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Norbord had 2 analyst reports since August 4, 2015 according to SRatingsIntel. On Tuesday, August 4 the stock rating was upgraded by Dundee Securities to “Neutral”. Sidoti initiated the shares of NBD in report on Thursday, October 1 with “Buy” rating. See Nuveen Build America Bond Opportunity Fund (NYSE:NBD) latest ratings:

Beaumont Financial Partners Llc decreased Abbott Laboratories (ABT) stake by 9.44% reported in 2017Q3 SEC filing. Beaumont Financial Partners Llc sold 12,374 shares as Abbott Laboratories (ABT)’s stock declined 3.42%. The Beaumont Financial Partners Llc holds 118,764 shares with $6.34M value, down from 131,138 last quarter. Abbott Laboratories now has $104.73 billion valuation. The stock increased 1.13% or $0.67 during the last trading session, reaching $60.17. About 7.85M shares traded or 12.40% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since February 19, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

The stock increased 0.45% or $0.1 during the last trading session, reaching $22.08. About 13,127 shares traded or 0.87% up from the average. Nuveen Build America Bond Opportunity Fund (NYSE:NBD) has 0.00% since February 19, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment decreased to 1.38 in 2017 Q3. Its down 0.79, from 2.17 in 2017Q2. It dived, as 3 investors sold Nuveen Build America Bond Opportunity Fund shares while 5 reduced holdings. 5 funds opened positions while 6 raised stakes. 2.40 million shares or 1.19% more from 2.38 million shares in 2017Q2 were reported. Sit Invest Assocs Inc reported 775,014 shares stake. Commonwealth Equity Svcs stated it has 0% of its portfolio in Nuveen Build America Bond Opportunity Fund (NYSE:NBD). Bancorporation Of America Corp De owns 0% invested in Nuveen Build America Bond Opportunity Fund (NYSE:NBD) for 108,292 shares. Icon Advisers Com stated it has 0.04% in Nuveen Build America Bond Opportunity Fund (NYSE:NBD). 101,685 are held by Horizon Kinetics Limited Liability Co. Tortoise Invest Limited Liability Co holds 6.29% of its portfolio in Nuveen Build America Bond Opportunity Fund (NYSE:NBD) for 940,078 shares. Thrivent Finance For Lutherans reported 300 shares or 0% of all its holdings. Cwm Ltd Liability holds 280 shares. Wells Fargo Co Mn owns 0% invested in Nuveen Build America Bond Opportunity Fund (NYSE:NBD) for 33,750 shares. 41,971 were accumulated by Morgan Stanley. Georgia-based Invesco has invested 0% in Nuveen Build America Bond Opportunity Fund (NYSE:NBD). Raymond James Associates reported 16,905 shares. Royal Bancshares Of Canada has invested 0% in Nuveen Build America Bond Opportunity Fund (NYSE:NBD). Optimum Investment stated it has 0.14% in Nuveen Build America Bond Opportunity Fund (NYSE:NBD).

Since September 22, 2017, it had 0 insider buys, and 7 insider sales for $31.71 million activity. Fussell Stephen R had sold 227,412 shares worth $14.27 million. Another trade for 62,460 shares valued at $3.31M was made by Salvadori Daniel Gesua Sive on Tuesday, September 26. $2.69M worth of Abbott Laboratories (NYSE:ABT) shares were sold by Ford Robert B. Contreras Jaime also sold $2.74M worth of Abbott Laboratories (NYSE:ABT) shares. 27,733 shares were sold by Blaser Brian J, worth $1.73 million on Wednesday, January 31.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It dropped, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Asset Management One Communications reported 0.35% in Abbott Laboratories (NYSE:ABT). Pettyjohn Wood And White Incorporated owns 65,333 shares or 1.29% of their US portfolio. Meiji Yasuda Life Insurance holds 47,597 shares. Illinois-based Peak6 Investments LP has invested 0.01% in Abbott Laboratories (NYSE:ABT). Heritage Investors Management Corp reported 57,032 shares. Armstrong Henry H Associate reported 30,952 shares or 0.3% of all its holdings. Wendell David Associate reported 212,252 shares. Afam Capital invested in 0.86% or 134,052 shares. Gulf International Bancshares (Uk), United Kingdom-based fund reported 550,350 shares. Janney Montgomery Scott Ltd Limited Liability Company stated it has 0.23% of its portfolio in Abbott Laboratories (NYSE:ABT). Daiwa Grp Inc Inc reported 158,878 shares. Cubist Systematic Strategies Limited Company stated it has 18,765 shares. State Of New Jersey Common Pension Fund D stated it has 1.00 million shares or 0.21% of all its holdings. Moreover, Country Tru Comml Bank has 0.01% invested in Abbott Laboratories (NYSE:ABT) for 3,656 shares. 5,120 are owned by Sta Wealth Mgmt Ltd Liability.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Saturday, August 29 by BTIG Research. Gabelli maintained the stock with “Buy” rating in Friday, July 21 report. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, July 23. RBC Capital Markets maintained the shares of ABT in report on Wednesday, January 24 with “Buy” rating. The stock of Abbott Laboratories (NYSE:ABT) has “Hold” rating given on Monday, July 10 by BMO Capital Markets. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, January 24 report. The firm earned “Buy” rating on Saturday, August 29 by Deutsche Bank. Piper Jaffray downgraded the stock to “Neutral” rating in Thursday, April 28 report. The stock of Abbott Laboratories (NYSE:ABT) earned “Overweight” rating by Barclays Capital on Thursday, October 19. The firm earned “Overweight” rating on Thursday, January 25 by JP Morgan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: